Evidence map›Paper›PMID 38472723›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024

Measurement properties of the EQ-5D-3L, EQ-5D-5L, and SF-6Dv2 in patients with late-onset Pompe disease.

Richard Huan Xu, Nan Luo, Dong Dong

Abstract read
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Quality-adjusted life expectancy norms for the Canadian population using EQ-5D-5L and SF-6Dv2.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Short Form 6 Dimensions (SF-6D): Development and Evolution.Applied health economics and health policy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Richard Huan XuDepartment of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong SAR, China.ORCID http://orcid.org/0000-0002-4720-5172
Nan LuoSaw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
Dong DongJC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. dongdong@cuhk.edu.hk.ORCID http://orcid.org/0000-0001-9784-6472

Funding

EuroQol Research Foundation 444-RA
6 · The paper itself

Abstract

objectiveThe objective of this study was to evaluate the psychometric properties of the EQ-5D (3L and 5L) and SF-6Dv2 in a group of Chinese patients with late-on Pompe disease (PD), and compare their performance in this patient group.

methodsThe data used in this study were obtained from a web-based and cross-sectional survey conducted in China. All participants completed the 3L, 5L, and SF-6Dv2. Information about their sociodemographic status and health conditions was also collected. The measurement properties were assessed by examining ceiling and floor effects, evaluating convergent validity, known-group validity, and test-retest reliability (Intraclass correlation coefficient [ICC] and Gwet's AC).

resultsA total of 117 PD patients completed the questionnaire. All dimensions of the 3L showed strong ceiling effects, ranging between 17.1 and 42.7%. All three measures showed good test-retest reliability, with ICC values ranging from 0.85 to 0.87. The Gwet's AC values showed that four out of five dimensions of the 3L showed very good agreement. All hypothesized correlations between the 3L, 5L, SF-6Dv2, and items of WHODAS were supported, indicating satisfactory convergent validity. The 5L showed stronger correlations (|r|= 0.53-0.84) with WHODAS than the other two measures. The outcomes of ANOVA indicated that the 5L had higher F-statistics than the 3L and SF-6Dv2, indicating a stronger discriminant ability to differentiate most condition groups.

conclusionThe 5L demonstrates lower ceiling and floor effects, higher discriminant ability, and better convergent validity than the SF-6Dv2 and 3L in patients with PD. In addition, the 5L may generate a larger utility gain compared to the other two instruments when conducting cost-effectiveness analysis.

Indexed as

Glycogen Storage Disease Type IIPsychometricsQuality of LifeAdultAgedChinaCross-Sectional StudiesFemaleHumansMaleMiddle AgedReproducibility of ResultsSurveys and QuestionnairesEQ-5DGlycogen storage diseaseMeasurement propertiesPompe diseaseSF-6D

Identifiers

PMID38472723
PMCPMC11512824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.